Neovasc to Sponsor Symposium on Reducer at EuroPCR
May 13 2021 - 9:11AM
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the
“Company”) (NASDAQ, TSX: NVCN) today announced that it will
sponsor a symposium presenting the latest long-term clinical data
on the Reducer™ (“Reducer”), highlighting its easy integration into
current cardiovascular and microvascular disease treatments. The
symposium titled, “Latest clinical evidence and practical aspects
to start Reducer therapy in your center,” will be presented at the
2021 EuroPCR, taking place digitally from May 18-20,
2021. EuroPCR is a leading opportunity for cardiologists
to exchange ideas and latest best practices.
The session will be available for registered
participants via a global livestream, from 1:00 to 2:00 PM EDT,
Thursday, May 20, 2021 on the “Valvular” channel, and via replay
for three months.
The session will be facilitated by Prof. Stefan
Verheye, MD, PhD, Antwerp Cardiovascular Center, Middelheim,
Antwerp, Belgium, and include presentations by:
- Prof. Martine Gilard, MD, Director of Interventional
Cardiology, Brest University Hospital, France
- Dr. Romain Didier, Interventional Cardiologist, Brest
University Hospital, France
- Prof. Jonathan Hill, MD, Consultant Interventional
Cardiologist at Royal Brompton & Harefield NHS Foundation
Trust, London, U.K.
- Prof. Tommaso Gori, MD, PhD, University Medical Center,
Mainz, Germany
- Dr. Francesco Giannini, Interventional Cardiologist,
Maria Cecilia Hospital, Cotignola, Italy
“Reducer therapy is an important tool for the
interventional cardiologist to treat patients with the challenging
diagnosis of refractory angina,” said Prof. Gilard. “We are at the
forefront of emerging treatments that offer new hope for patients
that, until now, have had no other options.”
About Reducer
The Reducer is CE-marked in the European Union for
the treatment of refractory angina, a painful and debilitating
condition that occurs when the arteries deliver an inadequate
supply of blood to the heart muscle, despite treatment with
standard revascularization or cardiac drug therapies. It affects
millions of patients worldwide, who typically lead severely
restricted lives as a result of their disabling symptoms, and its
incidence is growing. The Reducer provides relief of angina
symptoms by altering blood flow within the myocardium of the heart
and increasing the perfusion of oxygenated blood to ischemic areas
of the heart muscle. Placement of the Reducer is performed using a
minimally invasive transvenous procedure that is similar
to implanting a coronary stent and is completed in
approximately 20 minutes.
While the Reducer is not approved for commercial
use in the United States, the FDA granted Breakthrough Device
designation to the Reducer in October 2018. This designation is
granted by the FDA in order to expedite the development and review
of a device that demonstrates compelling potential to provide a
more effective treatment or diagnosis of life-threatening or
irreversibly debilitating diseases. In addition, there must be no
FDA approved treatments presently available, or the technology must
offer significant advantages over existing approved
alternatives.
Refractory angina, resulting in continued symptoms
despite maximal medical therapy and without revascularization
options, is estimated to affect 600,000 to 1.8 million Americans,
with 50,000 to 100,000 new cases per year.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara™ for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com.
For more information on and to register for
EuroPCR, please
visit: https://www.pcronline.com/Courses/EuroPCR
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Forward-Looking Statement
Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to, the
Company’s plans to sponsor the symposium and expectations as
to the growing cardiovascular marketplace. Forward-looking
statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of
historical trends, current conditions and expected future
developments, as well as other factors that the Company believes
are appropriate in the circumstances. Many factors could cause the
Company's actual results, performance or achievements to differ
materially from those expressed or implied by the forward
looking statements, including those described in the "Risk
Factors" section of the Company's Annual Information Form and in
the Management's Discussion and Analysis for the three months
ended March 31, 2021 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024